ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Future Genomics Technologies Logo

Future Genomics Technologies

We are one of the world’s first Oxford Nanopore Technologies certified sequencing providers. With our extensive knowledge we can offer solutions that cover the whole process of going from a biological sample to a complete genome sequence and annotation. Future Genomics Technologies, founded in 2017, is a collaboration between biotech company BaseClear and Leiden University.

Quick overview

Leiden, Netherlands

Founded in 2017

1-10 Employees

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Privately Held

Locations

1 Headquarter

Number of products

8 Products

Number of services

1 Service

Specialised areas

Nanopore sequencing, Bioinformatics, Nucleic acid extraction, Biotechnology

Products & services of Future Genomics Technologies

Future Genomics Technologies offers a wide range of products and services

Product: European eel genome - Future Genomics Technologies

Product

European eel genome - Future Genomics Technologies

Go to product >

Product: Portfolio - Future Genomics Technologies

Product

Portfolio - Future Genomics Technologies

Go to product >

Product: Nanopore sequencing technology - Future Genomics Technologies

Product

Nanopore sequencing technology - Future Genomics Technologies

Go to product >

Product: Solutions - Future Genomics Technologies

Service

Solutions - Future Genomics Technologies

Go to product >

Product: Sequencing by synthesis technology - Future Genomics Technologies

Product

Sequencing by synthesis technology - Future Genomics Technologies

Go to product >

Product: King cobra - Future Genomics Technologies

Product

King cobra - Future Genomics Technologies

Go to product >

Product: Yeast genome - Future Genomics Technologies

Product

Yeast genome - Future Genomics Technologies

Go to product >

Product: Knowledge - Future Genomics Technologies

Product

Knowledge - Future Genomics Technologies

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

Netherlands


Overall risk estimation:

Very low


ESG country scores

The ESG Data of countries are based on public sources

Environment

A

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of Future Genomics Technologies

Future Genomics Technologies operates in 1 country around the world

City: Leiden

State: South Holland

Country: Netherlands

Locations of Future Genomics Technologies

Get an overview of the locations of Future Genomics Technologies

Location

Country

State

City

Headquarter

Netherlands

South Holland

Leiden

Frequently asked questions (FAQ) about Future Genomics Technologies

Some frequent questions that have been asked about Future Genomics Technologies

The company headquarter of Future Genomics Technologies is located in Leiden, South Holland, Netherlands. It's worth noting, that the company may have more locations

As of the latest available information Future Genomics Technologies has around 1-10 employees worldwide.

Future Genomics Technologies was founded in 2017

The company Future Genomics Technologies has it's main focus in the industries of Biotechnology

Competitors of Future Genomics Technologies

Check out some interesting alternative companies to Future Genomics Technologies

Oxford Nanopore Technologies's Logo

Oxford Nanopore Technologies

Oxford, United Kingdom

251-500 Employees

2005

Our goal is to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our goal is to open up new applications that have a profound, positive impact on society, by providing a new generation of accessible technology. Nanopore sequencing offers advantages in all areas of research. Our offering includes DNA sequencing, as well as RNA and gene expression analysis and future technology for analysing proteins. Oxford Nanopore makes a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to use. Oxford Nanopore Technologies plc was founded in 2005 as a spin-out from the University of Oxford. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market. Oxford Nanopore is a public company, headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices in Cambridge (UK), New York, Cambridge, San Francisco (US), Singapore, Shanghai, Beijing, and a broader commercial presence that includes Japan, Germany, France and India.

Novogene's Logo

Novogene

Beijing, China

501-1000 Employees

2011

Novogene uses leading technology from Illumina, Pacific Biosciences, Oxford Nanopore and Life Technologies, in our state-of-the-art sequencing centers in California (USA), Cambridge (UK), Singapore and China. Reliable and high quality NGS data is a key component in genomics research. At Novogene, we use the most effective technology available from world leading providers including Illumina NovaSeq 6000, HiSeq, Oxford Nanopore, Ion Torrent , PacBio Revio and PacBio Sequel platforms. Over the years our NGS labs have developed optimized NGS processes and protocols to ensure the best possible scientific outcome for your research. Not only do we offer state of the art NGS technology, we also have the largest sequencing capacity in the world with an annual throughput of over 280,000 human WGS samples.

1010Genome's Logo

1010Genome

Singapore, Singapore

1-10 Employees

2015

We are a group of genomics enthusiast working towards a common goal of providing quality and quick next generation sequencing services and bioinformatics data analysis services. At 1010Genome we handle all sequencing technologies equally well. We provide sequencing services for Illumina, Ion Torrent, Pacbio, Oxford Nanopore, 10xGenomics and Sanger platforms. At 1010Genome, we understand the value of time in research. At 1010Genome, we are at the forefront of genomics, specializing in Next-Generation Sequencing (NGS) and advanced bioinformatics solutions. Our mission is to unlock the mysteries of the genome, enabling researchers and clinicians to make groundbreaking discoveries that shape the future of healthcare and scientific understanding. We deliver fast quality sequencing services at affordable rates across multiple next generation sequencing platforms such as, Illumina, Pacbio, Oxford Nanopore, Element & ParseBio. We are proud of our work and the results we have achieved for our clients.

Eurofins Genomics's Logo

Eurofins Genomics

Huntsville, United States

251-500 Employees

1990

Eurofins Genomics is part of Eurofins Scientific Group, an international provider of genomic services established around the core business lines of next generation sequencing, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. The company's main mission is focused on customer convenience and high quality services in industrial scale for the life science industries and academic research institutions around the world. Our NGS projects are being delivered using advanced Illumina NextSeq500 platform, HiSeq2500, MiSeq, PacBio sequel with high performance computational infrastructure. The laboratory and production facility has established profound know-how and proprietary protocols to cover a broad range of applications. Our production facility is ISO 9001: 2015 certified, which ensures you get the highest quality of products and services. Eurofins Genomics India's prime goal is to provide its customers with high-quality services, accurate results in fast turnaround time. With over 30,000 staff in over 375 laboratories across 41 countries, Eurofins Scientific is the world leader in food, environment, genomics and pharmaceutical products testing. Applied services for optimisation of production strains, organisms, processes and products.

AGTC Genomics's Logo

AGTC Genomics

Malaysia

11-50 Employees

2021

Our goal is to help solve the mysteries of how diseases are induced by genetics and epigenetics, and facilitate the advancement of precision medicine. Our products and services will enable consumers, researchers and clinicians to explore DNA on an entirely new scale, helping them to make informed decisions. We are a company at the intersection of biology and technology. We provide access to the world’s most advanced sequencing facility, no matter how large or small your organization is or where you are located in the world. We are dedicated to advancing genomic research and improving patient outcomes through our trusted services, and we are proud to be a partner of choice for some of the most respected institutions in the world. AGTC Genomics is dedicated to innovation, quality, rigor and transparency, providing outstanding solutions and support for human genome biomarker discovery. AGTC Genomics is a leading genomic center in the field of next-generation sequencing (NGS). Equipped with the latest world-leading technology platforms and professional scientific staff, AGTC Genomics is dedicated to assisting our clients while accelerating the precision medicine research and cancer diagnostics.

miBiome Therapeutics LLP's Logo

miBiome Therapeutics LLP

Mumbai, India

11-50 Employees

2019

We are an advanced science and deep tech start-up comprising of a passionate group of experienced scientists, doctors, business professionals and young coders. We are unlocking the power of genomics through deep technology in every sector. Our team of Next-Generation Sequencing (NGS) experts are always there to sequence DNA to understand life, disease, environment and more. Our team of highly qualified PhD experts can help navigate your sequencing journey.